** Shares of biotech firm Creative Medical Technology Holdings CELZ.O rise 16.1% to $5.33 premarket
** Co says its mid-term follow-up data showed its stem cell therapy, called StemSpine, was successful in treating chronic lower back pain and reducing opioid dependency
** Says the study shows significant improvements in pain levels and functional mobility
** Says no serious adverse events were reported
** Over 90% of patients reported no opioid use for pain management three years post-procedure, co says
** CELZ rose ~9% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.